Pharmaceutical Company Achieves Positive In-Vitro Testing Results Diabetes Drug

  Pharmaceutical Company Achieves Positive In-Vitro Testing Results Diabetes

Global Pharmaceutical & Biotechnology Outlook for 2013 Continues to be

PR Newswire

CORAL SPRINGS, Florida, January 31, 2013

CORAL SPRINGS, Florida, January 31, 2013 /PRNewswire/ --

Crown Marketing Pharmaceuticals (OTC: CWNM) announced today that it has
achieved positive in-vitro testing results of the most widely prescribed
Diabetes drug commonly known as Metformin.  Crown's Controlled Drug Delivery
Device (CDDT) is less than half the size of the 500mg dosage tablet, and may
reduce and ameliorate many of the gastrointestinal side effects of Metformin.
The most common adverse effects of Metformin are gastrointestinal upset
including diarrhea, cramps, nausea and vomiting. Crown Marketing
Pharmaceuticals (OTC: CWNM) believes it can significantly reduce or eliminate
these effects with its patented technology.

Patients also have issues about the taste and odor associated with the
medication. Common complaints are that it "smells fishy" and can leave a
metallic taste in the mouth. This is critical because it impacts patient
compliance-if it tastes or smells bad, patients oftentimes will not take the
medication as directed. Crown's CDDT can overcome these issues due to its
novel, diffusion based design and its impermable coating. According to IMS
figures, the total market sales for all forms of Metformin were $1.6 billion,
with sales of Metformin extended-release formulation alone accounting for over
$460 million last year.

Metformin is an pharmaceutical oral diabetes medicine that helps control blood
sugar levels originally sold as Glucophage. Metformin is for people with type
2 diabetes. Metformin is sometimes used in combination with insulin or other
medications, but it is not for treating type 1 diabetes. One of the more
common long-term complications of diabetes is diabetic renal disease ("renal"
refers to the kidneys). Also known as diabetic nephropathy, this condition is
a result of direct vascular abnormalities that accompany diabetes.  Keryx
Biopharmaceuticals Inc. (NASDAQ: KERX) announced this week that its kidney
disease drug, Zerenex, is also receiving positive signs as it has performed
better than a placebo in late-stage clinical trials. The New York company
said Monday that Zerenex showed a "highly statistically significant" change in
serum phosphorus levels compared with a placebo in patients with advanced
kidney failure who were on dialysis. Keryx Biopharmaceuticals Inc. (NASDAQ:
KERX) closed up yesterday at $8.49 per share on large trading volume over
49.1Million shares traded.

The Global Pharmaceutical & Biotechnology sector continues to remain
attractive, as cost containment initiatives, restructuring/deconsolidation,
share repurchase program, M&A, emerging market growth potential and dividend
policy continue to be encouraging. Over the next few years, the growth of the
industry would be shaped up by a battle between fundamental growth drivers
(Value added innovation) versus regulatory pressures to contain costs. In
Merger & Acquisition news, MAP Pharmaceuticals, Inc. (NASDAQ: MAPP) is a
biopharmaceutical company focused on developing and commercializing new
therapies to address undermet patient needs in neurology. The Company is
developing LEVADEX®, an orally inhaled investigational drug for the acute
treatment of migraine. Allergan, Inc. (NYSE: AGN) inked a deal with MAP
Pharmaceuticals, Inc. (NASDAQ: MAPP) to acquire the latter. As per the terms
of the deal, Allergan will acquire all the shares of MAP Pharmaceuticals for
$25.00 per share. The offer price represents premium of 60% over MAP
Pharmaceuticals' closing price back on Jan 22, 2012.

Another leader in the sector, Amarin Corporation (NASDAQ: AMRN) was originally
a small British drug delivery company, which evolved into a cardiovascular
drug development company and is now among the more promising biopharmaceutical
companies in the US. Vascepa (icosapent ethyl) for treatment of
hypertriglyceridemia is Amarin's first FDA approved product, whose market
introduction was announced by the company on January 24, 2013.
Hypertriglyceridemia refers to high blood level of triglycerides, a blood fat
that contributes to cardiovascular problems.

FinancialNewsMedia.comis leading provider of third party publishing & news
dissemination services. If you would like more information regarding our news
coverage solutions, please visit for more

DISCLAIMER: FN Media Group LLC (FNMG) is a third party publisher and news
dissemination service provider, which disseminates electronic information
through multiple online media channels. FNMG is NOT affiliated in any manner
with any company mentioned herein. FNMG and its affiliated companies are a
news dissemination and financial marketing solutions provider and are NOT a
registered broker/dealer/analyst/adviser, holds no investment licenses and may
NOT sell, offer to sell or offer to buy any security. FNMG's market updates,
news alerts and corporate profiles are NOT a solicitation or recommendation to
buy, sell or hold securities. The material in this release is intended to be
strictly informational and is NEVER to be construed or interpreted as research
material. All readers are strongly urged to perform research and due
diligence on their own and consult a licensed financial professional before
considering any level of investing in stocks. The companies that are
discussed in this release may or may not have approved the statements made in
this release. FNMG is not liable for any investment decisions by its readers
or subscribers. Investors are cautioned that they may lose all or a portion
of their investment when investing in stocks.

To comply with Section 17(b) of the Securities Act of 1933, FNMG shall always
disclose any compensation it has received, or expects to receive in the
future, for the dissemination of the information found herein on behalf of one
or more of the companies mentioned in this release. For disseminating this
release, FNMG was not compensated by any companies mentioned herein this

This release contains "forward-looking statements" within the meaning of
Section 27A of the Securities Act of 1933, as amended, and Section 21E the
Securities Exchange Act of 1934, as amended and such forward-looking
statements are made pursuant to the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. "Forward-looking statements"
describe future expectations, plans, results, or strategies and are generally
preceded by words such as "may", "future", "plan" or "planned", "will" or
"should", "expected," "anticipates", "draft", "eventually" or "projected". You
are cautioned that such statements are subject to a multitude of risks and
uncertainties that could cause future circumstances, events, or results to
differ materially from those projected in the forward-looking statements,
including the risks that actual results may differ materially from those
projected in the forward-looking statements as a result of various factors,
and other risks identified in a company's annual report on Form 10-K or 10-KSB
and other filings made by such company with the Securities and Exchange
Commission. You should consider these factors in evaluating the
forward-looking statements included herein, and not place undue reliance on
such statements. The forward-looking statements in this release are made as of
the date hereof and FNMG undertakes no obligation to update such statements.

Contact Information:

Company: FN Media Group, LLC
Contact email:
U.S. Phone: +1(954)345-0611

Press spacebar to pause and continue. Press esc to stop.